Mutations in CDKN2A were associated with worse recurrence-free survival (HR: 5.76; p < 0.001) and worse cancer-specific survival (HR: 2.94; p = 0.03) in multivariable analyses [17]. This evidence concerns the gene CDKN2A and cancer.